Aflac (AFL) to Release Earnings on Wednesday

Aflac (NYSE:AFL) will announce its earnings results after the market closes on Wednesday, May 1st. Analysts expect the company to announce earnings of $1.58 per share for the quarter. Investors interested in registering for the company’s conference call can do so using this link.

Aflac (NYSE:AFL) last issued its quarterly earnings results on Thursday, February 1st. The financial services provider reported $1.25 EPS for the quarter, missing the consensus estimate of $1.47 by ($0.22). The business had revenue of $3.78 billion during the quarter, compared to the consensus estimate of $4.44 billion. Aflac had a return on equity of 17.59% and a net margin of 24.92%. During the same period in the prior year, the firm earned $1.29 earnings per share. On average, analysts expect Aflac to post $6 EPS for the current fiscal year and $7 EPS for the next fiscal year.

Aflac Stock Performance

Shares of NYSE AFL opened at $83.75 on Wednesday. The company has a quick ratio of 0.06, a current ratio of 0.06 and a debt-to-equity ratio of 0.33. The business’s 50 day moving average is $82.43 and its two-hundred day moving average is $81.68. The company has a market cap of $48.19 billion, a P/E ratio of 10.81, a P/E/G ratio of 2.28 and a beta of 0.91. Aflac has a 12 month low of $64.10 and a 12 month high of $86.26.

Wall Street Analyst Weigh In

Several research analysts have commented on AFL shares. Morgan Stanley lifted their price target on Aflac from $80.00 to $84.00 and gave the stock an “equal weight” rating in a research report on Monday, April 15th. Wells Fargo & Company dropped their price target on Aflac from $83.00 to $81.00 and set an “equal weight” rating on the stock in a research report on Thursday, April 11th. Keefe, Bruyette & Woods lifted their price target on Aflac from $83.00 to $87.00 and gave the stock a “market perform” rating in a research report on Wednesday, April 10th. UBS Group lifted their price target on Aflac from $80.00 to $84.00 and gave the stock a “neutral” rating in a research report on Wednesday, January 10th. Finally, Piper Sandler boosted their price objective on Aflac from $90.00 to $95.00 and gave the company an “overweight” rating in a research report on Friday, April 5th. Three investment analysts have rated the stock with a sell rating, eight have given a hold rating and three have given a buy rating to the stock. According to data from MarketBeat.com, Aflac currently has a consensus rating of “Hold” and a consensus target price of $82.15.

Insider Buying and Selling at Aflac

In other Aflac news, SVP Albert Riggieri sold 8,000 shares of the company’s stock in a transaction on Thursday, March 14th. The stock was sold at an average price of $83.34, for a total value of $666,720.00. Following the sale, the senior vice president now directly owns 32,825 shares in the company, valued at $2,735,635.50. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Aflac news, Director Arthur Reginald Collins sold 3,000 shares of the business’s stock in a transaction on Thursday, February 22nd. The stock was sold at an average price of $79.73, for a total value of $239,190.00. Following the transaction, the director now owns 5,592 shares of the company’s stock, valued at $445,850.16. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, SVP Albert Riggieri sold 8,000 shares of the business’s stock in a transaction on Thursday, March 14th. The stock was sold at an average price of $83.34, for a total value of $666,720.00. Following the completion of the transaction, the senior vice president now directly owns 32,825 shares in the company, valued at approximately $2,735,635.50. The disclosure for this sale can be found here. Insiders have sold 46,493 shares of company stock worth $3,765,706 over the last three months. Company insiders own 0.80% of the company’s stock.

Aflac Company Profile

Aflac Incorporated, through its subsidiaries, provides supplemental health and life insurance products. The company operates through Aflac Japan and Aflac U.S. segments. The Aflac Japan segment offers cancer, medical, nursing care, work leave, GIFT, and whole and term life insurance products, as well as WAYS and child endowment plans under saving type insurance products in Japan.